Axolotl Biologix, a developer of regenerative medicine products, was acquired by a private equity firm. Terms were not disclosed.
The move comes as Axolotl prepares to initiate FDA clinical trials of current and developing biologic products with a range of applications in numerous segments, including orthopedics. Axolotl Biologix offers regenerative medicine treatment applications with clinical benefits known to stimulate cellular growth and repair of damaged cells and tissues.
Lines with orthopedic application include AxoBioFluid liquid allograft; AxoBioPRP, an autologous kit used to separate platelet-rich plasma from patient’s whole blood; AxoBioBMAC, an autologous kit used to separate bone marrow aspirate concentrated from the patient’s bone marrow draws; and AxoBioADIPOSE, an autologous kit used to separate patient’s adipocytes from adipose tissue. AxoBioFluid is available now, while the remaining products are planned for 2019 launch.
“The investment by the private equity company allows Axolotl Biologix to execute a more long-term strategy which includes conducting FDA approved clinical trials to further grow acceptance and adoption of our regenerative products,” said board member Gary Lauterbach, who has accepted the role of Interim CEO. Lauterbach’s goal is to expand distribution of Axolotl products beyond the present 500 offices and clinics in the U.S., and to secure new partners as a General Services Administration Contractor.
Axolotl Biologix, a developer of regenerative medicine products, was acquired by a private equity firm. Terms were not disclosed.
The move comes as Axolotl prepares to initiate FDA clinical trials of current and developing biologic products with a range of applications in numerous segments, including orthopedics. Axolotl Biologix...
Axolotl Biologix, a developer of regenerative medicine products, was acquired by a private equity firm. Terms were not disclosed.
The move comes as Axolotl prepares to initiate FDA clinical trials of current and developing biologic products with a range of applications in numerous segments, including orthopedics. Axolotl Biologix offers regenerative medicine treatment applications with clinical benefits known to stimulate cellular growth and repair of damaged cells and tissues.
Lines with orthopedic application include AxoBioFluid liquid allograft; AxoBioPRP, an autologous kit used to separate platelet-rich plasma from patient’s whole blood; AxoBioBMAC, an autologous kit used to separate bone marrow aspirate concentrated from the patient’s bone marrow draws; and AxoBioADIPOSE, an autologous kit used to separate patient’s adipocytes from adipose tissue. AxoBioFluid is available now, while the remaining products are planned for 2019 launch.
“The investment by the private equity company allows Axolotl Biologix to execute a more long-term strategy which includes conducting FDA approved clinical trials to further grow acceptance and adoption of our regenerative products,” said board member Gary Lauterbach, who has accepted the role of Interim CEO. Lauterbach’s goal is to expand distribution of Axolotl products beyond the present 500 offices and clinics in the U.S., and to secure new partners as a General Services Administration Contractor.
Copy to clipboard 
